Slippery womb molecule could hold key to IVF 'golden window'

Wednesday, 25 August, 2021

Slippery womb molecule could hold key to IVF 'golden window'

RMIT University researchers have found a way to better pinpoint the ‘golden window’ when a womb is ready for pregnancy — a discovery that could help boost IVF success rates.

The team identified a Teflon-like molecule that makes the surface of the womb slippery and prevents embryos from implanting, discovering that levels of this molecule on the womb’s surface decrease at a certain point in the menstrual cycle. This decrease allows the womb to become stickier, opening the ‘golden window’ for pregnancy success.

Correctly timing an embryo transfer is critical to the chance of achieving pregnancy, yet identifying the right moment in a woman’s cycle with absolute precision has remained a challenge, with IVF success rates remaining, on average, under 50%.

Before the RMIT discovery, scientists believed embryo implantation hinged on molecules that actively promoted the adhesion of an embryo to the wall of the uterus, but lead researcher Professor Guiying Nie said the team’s discovery changed long-held scientific thinking about embryo implantation.

“We’ve been looking for something that helps embryos stick when the vital part of the puzzle turned out to be a slippery molecule that has the opposite effect — it prevents them from sticking,” she said.

The research found a significant difference in IVF success rates when embryos were transferred while this molecule was present or absent on the surface of the uterus.

Professor Nie, who leads the Implantation and Pregnancy Research Laboratory in the School of Health and Biomedical Sciences at RMIT, said, “Every embryo is precious for families struggling with infertility, so getting the timing right is critical.

“We hope with further development our discovery could help clinicians identify precisely when each patient has the greatest chance of achieving pregnancy, delivering fully personalised IVF treatment.”

The findings, published in the journals Fertility and Sterility and Human Reproduction, could have significant implications for IVF treatment and success rates.

Pregnancy success rates

The retrospective clinical study, co-designed by Professor Nie and Professor Luk Rombauts from Monash IVF, examined levels of the anti-implantation molecule, known as podocalyxin (PCX), in the endometrium of 81 women undergoing IVF treatment.

A biopsy of the uterus was taken at the mid-luteal phase (about seven days after ovulation) of the women’s menstrual cycle, one full cycle before a frozen embryo was transferred.

While the women with low levels of PCX had a 53% pregnancy success rate, those women where the molecule had not been reduced had a success rate of just 18%.

Professor Rombauts said measuring levels of PCX at the mid-luteal phase can be used as a screening test but it could also indicate a reason for infertility, making the molecule a potential target for treatment.

“These findings offer a promising path for us to both improve IVF success rates and potentially treat an underlying cause of infertility,” he said.

The research team has already begun work to better understand the role of PCX and how it is regulated in the body, with the aim of developing infertility treatments.

Professor Nie said the analysis of this molecule could be done in a standard pathology laboratory, making it relatively cost-effective to implement a future screening test.

“The only way we can currently test for PCX is through biopsies of tissue, which cannot be taken at the time when embryos are transferred,” she said.

“We need further research to develop non-invasive and real-time approaches for measuring PCX on the day of embryo transfer. Our hope is to deliver a simple test that can help patients and boost the precision and personalisation of IVF treatment.”

Image caption: Magnified and colourised image of a human embryo. Image credit: RMIT University.

Related News

Digital resource to help clinicians prevent childhood obesity

Dietitian and University of Queensland Research Fellow Dr Oliver Canfell and her team have...

Omicron: understanding the level of severity will take days to weeks — WHO

The new Omicron COVID-19 variant has been declared to be "of concern" by the World...

Anaphylaxis: ED visits up by 51%, new care standard released

The Australian Commission on Safety and Quality in Health Care (the Commission) has released the...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd